IMH (Immune-Mediated Hematology) Marketing Group, Wayrilz ITP Brand Manager
At RBD franchise, we are serving people with intractable rare blood disorders by delivering innovative therapies and additional values. Within the franchise, IMH marketing is responsible for managing two brands which are, in-market brand Cablivi (for the treatment of aTTP/iTTP), and pre-launch brand Wayrilz (for ITP).
Wayrilz is a first-in-class & best-in-class BTK inhibitor for the treatment of ITP which has been approved by PMDA in June 2026. Wayrilz is a strategically prioritized product within the Specialty Care Business Unit also known as one of the Big 12. In addition to ITP, there are also other indications currently under development.
The mission of Wayrilz Brand Manager is to contribute to patients with ITP and associates and co-working with internal/external partners, including global brand team, to jointly create strategy, and execute tactical plans which are aligned with the strategy.
For the successful launch of Wayrilz in ITP, massive market shaping is critical in terms of transforming the way HCPs views and treats the condition, while empowering patients to seek for better QoL.
Hence, this is an exciting opportunity for those who are willing to delivering meaningful value for the society and aiming to grow his or her career through such job experience.
IMH ; immune-mediated hematology, aTTP/iTTP ; acquired/immune thrombotic thrombocytopenic purpura, ITP ; immune thrombocytopenia